1 |
Nagy, G., Koncz, A. and Perl, A. : T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 25, 123 (2005).
DOI
|
2 |
Chae, B. S. and Shin, T. Y. : Immunoregulatory abnormalities of T cells and hyperreactivity of B cells in the in vitro immune response in pristane-induced lupus mice. Arch. Pharm. Res. 30, 191 (2007).
DOI
|
3 |
Xu, L., Zhang, L., Yi, Y., Kang, H. K. and Datta, S. K. : Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10, 411 (2004).
DOI
|
4 |
Takeno, M., Nagafuchi, H., Kaneko, S., Wakisaka, S., Oneda, K., Takeba, Y., Yamashita, N., Suzuki, N., Kaneoka, H. and Sakane, T. : Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J. Immunol. 158, 3529 (1997).
|
5 |
Reininger, L., Santiago, M. L., Takahashi, S., Fossati, L. and Izui, S. : T helper cell subsets in the pathogenesis of systemic lupus erythematosus. Ann. Med. Interne. (Paris) 147, 467 (1996).
|
6 |
Ishikawa, S., Akakura, S., Abe, M., Terashima, K., Chijiiwa, K., Nishimura, H., Hirose, S. and Shirai, T. : A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance. J. Immunol. 161, 1267 (1998).
|
7 |
Portales-Perez, D., Gonzalez-Amaro, R., Abud-Mendoza, C. and Sanchez-Armass, S. : Abnormalities in CD69 expression, cytosolic pH and during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 6, 48 (1997).
DOI
|
8 |
Crispin, J. C., Martinez, A., de Pablo, P., Velasquillo, C. and Alcocer-Varela, J. : Participation of the CD69 antigen in the Tcell activation process of patients with systemic lupus erythematosus. Scand. J. Immunol. 48, 196 (1998).
DOI
|
9 |
Takeuchi, T., Tsuzaka, K., Abe, T., Yoshimoto, K., Shiraishi, K., Kameda, H. and Amano, K. : T cell abnormalities in systemic lupus erythematosus. Autoimmunity 38, 339 (2005).
DOI
|
10 |
Jordan, N. and D'Cruz, D. : Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther. Adv. Musculoskelet Dis. 7, 234 (2015).
DOI
|
11 |
Steiman, A. J., Gladman, D. D., Ibanez, D., Noamani, B., Landolt-Marticorena, C., Urowitz, M. B. and Wither, J. E. : Lack of Interferon and proinflammatory cyto/chemokines in serologically active clinically quiescent systemic lupus erythematosus. J. Rheumatol. 42, 2318 (2015).
DOI
|
12 |
Aringer, M. and Smolen, J. S. : SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res. Ther. 5, 172 (2003).
|
13 |
Liang, B., Gardner, D. B., Griswold, D. E., Bugelski, P. J. and Song, X. Y. : Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119, 296 (2006).
DOI
|
14 |
Chun, H. Y., Chung, J. W., Kim, H. A., Yun, J. M., Jeon, J. Y., Ye, Y. M., Kim, S. H., Park, H. S. and Suh, C. H. : Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27, 461 (2007).
DOI
|
15 |
Dean, G. S., Tirrell-Price, J., Crawley, E. and Isenberg, D. A. : Cytokines and systemic lupus erythematosus. Ann. Rheum. Dis. 59, 243 (2000).
DOI
|
16 |
Haas, C., Ryffel, B. and Le Hir, M. : IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J. Immunol. 160, 3713 (1998).
|
17 |
Richards, H. B., Satoh, M., Shaw, M., Libert, C., Poli, V. and Reeves, W. H. : Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188, 985 (1998).
DOI
|
18 |
Li-Weber, M. : New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat. Rev. 35, 57 (2009).
DOI
|
19 |
Tsai, C. Y., Wu, T. H., Tsai, S. T., Chen, K. H., Thajeb, P., Lin, W. M., Yu, H. S. and Yu, C.L. : Cerebrospinal fluid interleukin- 6, prostaglandin and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand. J. Rheumatol. 23, 57 (1994).
DOI
|
20 |
Chae, B. S., Shin, T. Y., Kim, D. K., Eun, J. S., Leem, J. Y. and Yang, J. H. : Prostaglandin -mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice. Arch. Pharm. Res. 31, 503 (2008).
DOI
|
21 |
Gao, Z., Huang, K., Yang, X. and Xu, H. : Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim. Biophys. Acta. 1472, 643 (1999).
DOI
|
22 |
Wang, H. and Liu, D. : Baicalin inhibits high-mobility group box 1 release and improves survival in experimental sepsis. Shock 41, 324 (2014).
DOI
|
23 |
Zhu, J., Wang, J., Sheng, Y., Zou, Y., Bo, L., Wang, F., Lou, J., Fan, X., Bao, R., Wu, Y., Chen, F., Deng, X. and Li, J. : Baicalin improves survival in a murine model of polymicrobial sepsis via suppressing inflammatory response and lymphocyte apoptosis. PLoS One 7, e35523 (2012).
DOI
|
24 |
Liu, L. L., Gong, L. K., Wang, H., Xiao, Y., Wu, X. F., Zhang, Y. H., Xue, X., Qi, X. M. and Ren, J. : Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock. Biochem. Pharmacol. 75, 914 (2008).
DOI
|
25 |
Beebe, A. M., Cuab, D. J. and de Waal Malefyt, R. : The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine & Growth Factor Reviews 13, 403 (2002).
DOI
|
26 |
Svenungsson, E., Fei, G. Z., Jensen-Urstad, K., de Faire, U., Hamsten, A. and Frostegard, J. : TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12, 454 (2003).
DOI
|
27 |
Xu, J., Huang, R., Yang, Y. J., Jin, S. J. and Zhang, J. F. : Effects of baicalin on apoptosis in rats with autoimmune encephalomyelitis. Zhongguo Dang Dai Er Ke Za Zhi 13, 665 (2011).
|
28 |
Yang, J., Yang, X. and Li, M. : Baicalin, a natural compound, promotes regulatory T cell differentiation. BMC Complement Altern. Med. 12, 64 (2012).
|
29 |
Shacter, E., Arzadon, G. K. and Williams, J. : Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood 80, 194 (1992).
|
30 |
Chae, B. S. : Baicalin amelirates dysimmunoregulation in pristane-induced lupus mice: production of IL-6 and PGE2 and activation of T cells. Nat. Prod. Sci. 17, 354 (2011).
|
31 |
Qu, H., Bian, W. and Xu, Y. : A novel NF- inhibitor, DHMEQ, ameliorates pristane-induced lupus in mice. Exp. Ther. Med. 8, 100 (2014).
DOI
|
32 |
Miyagaki, T., Fujimoto, M. and Sato, S. : Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. Int. Immunol. 27, 495 (2015).
DOI
|
33 |
Sim, J. H., Kim, H. R., Chang, S. H., Kim, I. J., Lipsky, P. E. and Lee, J. : Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus. Arthritis Res. Ther. 17, 190 (2015).
DOI
|
34 |
Kalinski, P. : Regulation of immune responses by prostaglandin . J. Immunol. 188, 21 (2012).
DOI
|
35 |
Piliero, P. and Furie, R. : Functional asplenia in systemic lupus erythematosus. Semin. Arthritis Rheum. 20, 185 (1990).
DOI
|
36 |
Hinson., R. M., Williams, J. A. and Shacter, E. : Elevated interleukin 6 is induced by prostaglandin in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. U S A 93, 4885 (1996).
DOI
|
37 |
Mene, P., Pecci, G., Cinotti, G. A., Pugliese, G., Pricci, F. and Pugliese, F. : Eicosanoid synthesis in peripheral blood monocytes: a of disease activity in lupus nephritis. Am. J. Kidney Dis. 32, 778 (1998).
DOI
|
38 |
Dillon, A. M., Stein, H. B. and English, R. A. : Splenic atrophy in systemic lupus erythematosus. Ann. Intern. Med. 96, 40 (1982).
DOI
|
39 |
Yang, X., Sun, B., Wang, H., Yin, C., Wang, X. and Ji, X. : Increased serum IL-10 in lupus patients promotes apoptosis of T cell subsets via the caspase 8 pathway initiated by Fas signaling. J. Biomed. Res. 29, 232 (2015).
|
40 |
Panarese, A., D'Andrea, V., Pironi, D. and Filippini, A. : Thymectomy and systemic lupus erythematosus (SLE). Ann. Ital. Chir. 85, 617 (2014).
|
41 |
Gottschalk, T. A., Tsantikos, E. and Hibbs, M. L. : Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front. Immunol. 6, 550 (2015).
|
42 |
Mathian, A., Hie, M., Cohen-Aubart, F. and Amoura, Z. : Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75, 835 (2015).
DOI
|
43 |
Balomenos, D., Rumold, R. and Theofilopoulos, A. N. : Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101, 364 (1998).
DOI
|
44 |
Harigai, M., Kawamoto, M., Hara, M., Kubota, T., Kamatani, N. and Miyasaka, N. : Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J. Immunol. 181, 2211 (2008).
DOI
|